generative artificial intelligence tool maia (Pfizer Inc)
86
Structured Review
Pfizer Inc
generative artificial intelligence tool maia
Generative Artificial Intelligence Tool Maia, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/generative+artificial+intelligence/ai+artificial+generative+intelligence/pm42248437-27-10-9
Average 86 stars, based on 1 article reviews
Generative Artificial Intelligence Tool Maia, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/generative+artificial+intelligence/ai+artificial+generative+intelligence/pm42248437-27-10-9
Average 86 stars, based on 1 article reviews
generative artificial intelligence tool maia - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial. Article Snippet: Prof Silvio Danese, MD, Martina Goetsch, MD, Prof Laurent Peyrin-Biroulet, MD, Prof Andres J. Yarur, MD, Prof Marla Dubinsky, MD, Prof David T. Rubin, MD, Prof Brian G. Feagan, MD, Prof Geert D’Haens, MD, Filip Baert, MD, Krisztina Lazin, MD, Guibao Gu, MD, Jin Yu, PharmD, Nervin Lawendy, PharmD, Chuanbo Zang, PhD, Wenjin Wang, PhD, Sujatha Menon, PhD, Ernest H. Law, PharmD, Irene Modesto, MD, Karolina Wosik, PhD, Sarah Sidhu, MD, Wojciech Niezychowski, MD, Prof Séverine Vermeire, MD Article Title: Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols. Article Snippet: Phase I investigation of the enhancer of zeste homolog 2 inhibitor, mevrometostat, plus enzalutamide showed promising antitumor activity versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) (NCT03460977).. MEVPRO-1 (open label) and MEVPRO-2 (double blind) are ongoing, global, phase III, randomized studies evaluating efficacy and safety of mevrometostat plus enzalutamide in patients with mCRPC.. MEVPRO-1 will include ~600 patients with ≥12 weeks of prior abiraterone treatment, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–2, testosterone ≤50 ng/dL, and life expectancy ≥6 months. Article Title: Risk of Safety Events in Vitiligo Patients: A Retrospective Real-World Data Study in the US. Article Snippet: This study was funded by Pfizer Inc. Support for third- party medical writing assistance, provided by Claire Stedden, PhD, of Nucleus Global, an Article Title: Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US Article Snippet: Article Title: EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. Article Snippet: TECHNOLOGIES IN THE WRITING PROCESS The initial outline of the body of the manuscript was drafted with the assistance of a proprietary Article Title: Lorlatinib in patients with ALK -positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study. Article Snippet: Aims: This post-approval study was conducted to confirm efficacy of lorlatinib in anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) that progressed on 1 prior secondgeneration ALK tyrosine kinase inhibitor.. Patients & methods: In this phase IV open-label study, patients with ALK-positive metastatic NSCLC that progressed on first-line alectinib or ceritinib received lorlatinib 100 mg once daily.. Primary endpoint was objective response rate (ORR) per RECIST 1.1 by independent central review (ICR). Article Title: Clinical Characteristics and Treatment Patterns in Patients With Vitiligo. Article Snippet: Additional Information: Pfizer’s |